Boston Trust Walden Corp Buys 7,542 Shares of Zoetis Inc. (NYSE:ZTS)

Boston Trust Walden Corp increased its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 18.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 49,018 shares of the company's stock after purchasing an additional 7,542 shares during the period. Boston Trust Walden Corp's holdings in Zoetis were worth $8,071,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Schroder Investment Management Group increased its position in shares of Zoetis by 2.6% during the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock valued at $40,036,000 after purchasing an additional 6,169 shares during the last quarter. Vanguard Group Inc. raised its position in Zoetis by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock worth $6,739,905,000 after acquiring an additional 120,158 shares during the period. Portside Wealth Group LLC boosted its stake in shares of Zoetis by 24.7% during the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock worth $5,550,000 after acquiring an additional 6,672 shares during the last quarter. Oppenheimer & Co. Inc. increased its stake in shares of Zoetis by 72.4% in the 4th quarter. Oppenheimer & Co. Inc. now owns 93,114 shares of the company's stock worth $15,171,000 after purchasing an additional 39,114 shares in the last quarter. Finally, OFI Invest Asset Management purchased a new position in Zoetis during the fourth quarter valued at $37,298,000. Institutional investors own 92.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and lowered their price objective for the company from $165.00 to $160.00 in a research report on Wednesday. Piper Sandler raised their target price on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Monday, May 12th. UBS Group dropped their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Finally, Wall Street Zen raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Zoetis currently has an average rating of "Buy" and an average price target of $212.13.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president now directly owns 15,129 shares of the company's stock, valued at $2,571,930. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.18% of the company's stock.

Zoetis Trading Up 1.4%

Shares of ZTS stock opened at $157.26 on Friday. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 1.12. The stock has a market capitalization of $70.01 billion, a price-to-earnings ratio of 28.23, a price-to-earnings-growth ratio of 2.57 and a beta of 0.94. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The stock's 50-day moving average price is $159.58 and its 200-day moving average price is $163.40.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The company's revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.38 EPS. Equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.27%. Zoetis's payout ratio is currently 35.91%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.